15 Top ADHD Medication Pregnancy Bloggers You Should Follow
ADHD Medication During Pregnancy and Breastfeeding
The decision to stop or keep ADHD medications during pregnancy and nursing is a challenge for women suffering from the condition. There aren't enough data regarding how exposure over time may affect a pregnant fetus.
A study recently published in Molecular Psychiatry shows that children exposed to ADHD medication during utero do not develop neurological disorders such as hearing or vision impairment seizures, febrile seizures or IQ impairment. The authors acknowledge the need for higher-quality research.
Risk/Benefit Analysis
Pregnant women who take ADHD medications must weigh the benefits of taking them against the potential risks to the foetus. Physicians do not have the necessary data to provide clear recommendations but they can provide information on benefits and risks that can help pregnant women make informed decisions.
A study published in Molecular Psychiatry found that women who took ADHD medications during their early pregnancy did not have an increased risk of fetal heart malformations or major structural birth defects. adhd depression medication conducted a large sample-based case control study to compare the incidence of structural defects that were major in infants who were born to mothers who were taking stimulants during pregnancy. Pediatric cardiologists, clinical geneticists and other experts examined the cases to ensure that the classification was accurate and to reduce any bias.
The study of the researchers was not without limitations. The most important issue was that they were not able to differentiate the effects of the medication from the disorder that is underlying. This makes it difficult to know whether the small differences observed in the exposed groups are due to the use of medication or confounding by comorbidities. Additionally the researchers did not examine the long-term outcomes of offspring.
The study showed that infants whose mother took ADHD medication during pregnancy had a greater risk of being admitted to the neonatal care unit (NICU) as compared to mothers who did not take any medication during pregnancy, or had quit taking the medication prior to or during pregnancy. This was due to central nervous system disorders. The increased risk of admission was not affected by the stimulant medication that was used during pregnancy.
Women who were taking stimulant ADHD medication during pregnancy also had an increased chance of having a caesarean delivery or having a child with low Apgar score (less than 7). These increases didn't appear to be affected by the type of medication that was used during pregnancy.
Researchers suggest that the minor risk of using ADHD medications during early pregnancies may be offset by the more beneficial outcomes for both mother and baby from continuing treatment for the woman's condition. Physicians should discuss this with their patients and, where possible, help them develop strategies for improving their coping skills which can reduce the impact of her disorder on her daily functioning and relationships.
Interactions with Medication
Doctors are increasingly confronted with the dilemma of whether to continue treatment or stop during pregnancy as more women are diagnosed with ADHD. Most of the time, these decisions are made without any evidence that is clear and definitive in either case, which means that doctors must weigh what they know from their own experiences, those of other doctors, and what research suggests on the subject and their best judgment for each patient.
Particularly, the issue of potential risks to the infant can be difficult. The research on this subject is based on observation rather than controlled studies and many of the findings are in conflict. In addition, most studies limit their analysis to live births, which could underestimate severe teratogenic effects that cause abortion or termination of the pregnancy. The study discussed in the journal club addresses these issues, by examining both information on deceased and live births.
Conclusion A few studies have revealed an association between ADHD medications and certain birth defects However, other studies haven't established a link. Most studies show that there is a neutral, or slightly negative, effect. In every case it is imperative to conduct a thorough study of the potential risks and benefits must be performed.
It can be difficult, if not impossible, for women with ADHD to stop taking their medication. In a recent article published in Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can lead to depression and feelings of being isolated. A loss of medication may also affect the ability to drive safely and to perform work-related tasks which are crucial aspects of daily life for those with ADHD.
She recommends women who are unsure about whether to continue or stop medication in light of their pregnancy consider educating family members, friends, and coworkers on the condition, its impact on daily functioning, and on the advantages of staying on the current treatment plan. It can also help women feel more confident in her decision. Certain medications can pass through the placenta. If the patient decides to stop taking her ADHD medication while pregnant and breastfeeding, it is crucial to be aware that the medication could be passed on to her baby.
Birth Defects and Risk of
As the use and use of ADHD medication to treat symptoms of attention deficit hyperactivity disorder (ADHD), increases, so does concern about the possible effects of the drugs on foetuses. A study that was published in the journal Molecular Psychiatry adds to the body of information on this topic. With two massive data sets researchers were able look at more than 4.3 million pregnancies to determine whether the use of stimulant medications increased the risk of birth defects. Although the risk overall remains low, the scientists discovered that the first-trimester exposure to ADHD medications was linked to an increase in the risk of specific heart defects, such as ventriculoseptal defect (VSD).
The authors of the study found no association between early medication use and other congenital abnormalities, such as facial clefting or club foot. The findings are in line with previous studies showing a small but significant increase in the risk of cardiac malformations among women who began taking ADHD medications before the time of pregnancy. The risk was higher in the later part of pregnancy, when many women are forced to stop taking their ADHD medications.
Women who used ADHD medications during the first trimester of pregnancy were also more likely to undergo caesarean sections, a low Apgar score after delivery and a baby who required breathing assistance during birth. The researchers of the study were unable to remove bias in selection since they restricted the study to women with no other medical conditions that could have contributed to the findings.
Researchers hope that their research will provide doctors with information when they meet pregnant women. They suggest that although discussing the risks and benefits is crucial however, the decision to stop or maintain treatment must be based on each woman's requirements and the severity of her ADHD symptoms.
The authors caution that, although stopping the medication is a possibility to consider, it is not recommended due to the high prevalence of depression and other mental problems in women who are expecting or who have recently given birth. Additionally, the research suggests that women who decide to stop taking their medication are more likely to experience a difficult time adapting to life without them following the birth of their baby.
Nursing
The responsibilities that come with being a new mother can be overwhelming. Women with ADHD who must work through their symptoms while attending doctor appointments as well as getting ready for the arrival of their child and getting used to new routines at home may face a lot of challenges. Many women choose to continue taking their ADHD medication during pregnancy.
The majority of stimulant drugs pass through breast milk in very small quantities, so the risk to infant who is breastfeeding is low. The rate of exposure to medication will vary based on the dosage and frequency of administration as well as the time of day. In addition, individual medications enter the infant's system differently through the gastrointestinal tract and breast milk and the impact of this on a newborn isn't fully understood.
Some doctors may decide to stop stimulant medication during a woman’s pregnancy due to the lack of research. It's a difficult choice for the woman, who must weigh the advantages of her medication against the risk to the embryo. As long as there is no more information, doctors should inquire with all pregnant patients about their experience with ADHD and whether they are planning or taking to take medication during the perinatal time.
A growing number of studies have proven that the majority of women are able to safely continue to take their ADHD medication while they are pregnant and nursing. In response, a growing number of patients are opting to do so. They have concluded after consulting with their doctors that the benefits of retaining their current medication outweigh any risk.
It's important for women with ADHD who are considering breastfeeding to seek out a specialist psychiatrist's guidance prior to becoming pregnant. They should discuss the medication they are taking with their physician and discuss the pros and cons of continuing treatment. This includes non-pharmacological strategies. Psychoeducation should also be offered to help pregnant people with ADHD recognize their symptoms and the root cause Learn about the available treatment options and reinforce existing strategies for coping. This should be a multidisciplinary effort together with obstetricians, GPs, and psychiatry. Pregnancy counseling should consist of a discussion of a treatment plan for the mother as well as the child, monitoring of signs of deterioration and, if necessary modifications to the medication regimen.